DAVID NELSON to Hepacivirus
This is a "connection" page, showing publications DAVID NELSON has written about Hepacivirus.
Connection Strength
1.369
-
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr; 61(4):1127-35.
Score: 0.401
-
Novel interferons for treatment of hepatitis C virus. Clin Liver Dis. 2009 Aug; 13(3):351-63.
Score: 0.272
-
Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection. Sci Rep. 2022 10 27; 12(1):18094.
Score: 0.170
-
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology. 2021 12; 74(6):2952-2964.
Score: 0.157
-
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med. 2017 10 12; 377(15):1448-1455.
Score: 0.120
-
Expression of an IRF-3 fusion protein and mouse estrogen receptor, inhibits hepatitis C viral replication in RIG-I-deficient Huh 7.5 cells. Virol J. 2011 Sep 21; 8:445.
Score: 0.079
-
Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J. 2005 Sep 07; 2:80.
Score: 0.052
-
Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. J Interferon Cytokine Res. 2005 Sep; 25(9):528-39.
Score: 0.052
-
Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology. 2003 May; 37(5):1180-8.
Score: 0.044
-
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1594-603.
Score: 0.024